Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research
March 4th 2024In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Listen
FDA to Review Inavolisib Combo for HR-Positive, HER2-Negative Breast Cancer
May 22nd 2024The Food and Drug Administration granted a breakthrough therapy designation to inavolisib plus Ibrance and fulvestrant for HR-positive, HER2-negative locally advanced or metastatic breast cancer.
Read More